AbbVie has agreed to pay China-based RemeGen up to $5.6 billion to license RC148, a next-generation PD-1/VEGF bispecific antibody aimed at treating advanced solid tumors, marking one of the largest cross-border oncology licensing deals announced so far in 2026. Under the agreement, AbbVie will receive exclusive rights to develop, manufacture, and commercialize RC148 outside Greater … AbbVie Bets $5.6 Billion on PD-1×VEGF Bispecifics, Licensing RemeGen’s RC148 to Expand Its Oncology Arsenal Read More » To access this post, you must purchase Individual Subscriber Yearly or Enterprise Subscriber.